Introduction：Basic information about Fentanyl citrate CAS 990-73-8, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Fentanyl citrate Basic information
| Product Name: | Fentanyl citrate |
| Synonyms: | fentaz;mcn-jr4263;mcn-jr-4263-49;n-(1-phenethyl-4-piperidinyl)propionanilidedihydrogencitrate;n-(1-phenethyl-4-piperidyl)-propionanilidcitrate(1:1);n-(1-phenethyl-4-piperidyl)propionanilidecitrate;n-(1-phenethyl-4-piperidyl)propionanilidedihydrogencitrate;phentanylcitrate |
| CAS: | 990-73-8 |
| MF: | C28H36N2O8 |
| MW: | 528.59 |
| EINECS: | 213-588-0 |
| Product Categories: | API;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 990-73-8.mol |
|
Fentanyl citrate Chemical Properties
| Melting point | 153-156°C |
| Fp | 11 °C |
| storage temp. | 2-8°C |
| solubility | Soluble in water, freely soluble in methanol, sparingly soluble in ethanol (96 per cent). |
| form | Powder |
| color | Crystals |
| Water Solubility | Soluble to 40 mM in water |
| CAS DataBase Reference | 990-73-8(CAS DataBase Reference) |
Safety Information
| Hazard Codes | T+,T,F |
| Risk Statements | 26/27/28-42/43-39/23/24/25-23/24/25-11-36/37 |
| Safety Statements | 7-16-36/37-45-36/37/39-26 |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | UE5600000 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 2933330000 |
| Toxicity | LD50 in mice (mg/kg): 11.2 i.v.; 62 s.c. (Gardocki, Yelnosky) |
Fentanyl citrate Usage And Synthesis
| Chemical Properties | White Powder |
| Uses | Fentanyl citrate can be used as an analgesic. |
| Definition | ChEBI: The citric acid salt of fentanyl, comprising equimolar amounts of citric acid and fentanyl. A mu-opioid receptor agonist, it is a potent opioid analgesic used in the management of labour pain, postoperative pain, and chronic intractable cancr pain. It is also widely used as the analgesic component of balanced anaesthesia. |
| Brand name | Actiq (Cephalon); Sublimaze (Akorn). |
| Biological Activity | Potent and selective μ -opioid receptor agonist (K i values are 7.0, 151 and 470 nM for μ -, δ - and κ -opioid receptors respectively). Displays antinociceptive activity in vivo . |
| Clinical Use | A fentanyl patch is available for the treatment of severe chronic pain. This dosage form deliversfentanyl transdermally and provides effective analgesia for periods of up to 72 hours. In 1999,fentanyl also became available in a lollipop dose form for absorption from the oral cavity.Fentanyl's short duration of action after parenteral dose is caused by redistribution rather than bymetabolism or excretion. Repeated doses of fentanyl can result in accumulation and toxicities.Elderly patients usually are more sensitive to fentanyl and require lower doses.
Opioids have a wide spectrum of P-glycoprotein (P-gp) activity, acting as both substrates andinhibitors, which might contribute to their varying CNS-related effects. Although fentanyl,sufentanil, and alfentanil did not behave as P-gp substrates, they inhibited the in vitroP-gp–mediated efflux of drugs known to be P-gp transported, such as digoxin, increasing theirblood levels and the potential for important drug interactions by inhibition of P-gp effluxtransporter. |
| Safety Profile | Poison by ingestion, subcutaneous, and intravenous routes. When heated to decomposition it emits toxic fumes of NOx. See also PHENTANYL. |
Fentanyl citrate Preparation Products And Raw materials
